Preclinical study reveals MYC-driven alarmin pathway activation in myeloproliferative neoplasms with trisomy 8, highlighting distinct therapeutic targets.
Figure S1. Landscape of somatic mutations and cytogenetics in Moffitt MF cohort. Figure S2. Effects of enforced MYC expression in HSCs in vivo. Figure S3. MYC-induced changes in hematopoietic sub-populations and colony forming potential. Figure S4. The JAK/STAT, PI3K/AKT, MEK/ERK, and alarmin pathways in MYC-driven MF.
No takes yet. Share an insight, caveat, or question.
Vincelette et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: